TY - STD TI - Ansell SM. Hodgkin lymphoma: diagnosis and treatment. In: Mayo Clinic proceedings (2015). (Vol. 90, no. 11, pp. 1574-1583). Elsevier. ID - ref1 ER - TY - STD TI - Hefazi M, Litzow MR. Recent advances in the biology and treatment of T cell acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2018:1–10. ID - ref2 ER - TY - STD TI - Soverini S, Mancini M, Bavaro L, Cavo M, Martinelli G. Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Mol Cancer. 17(1). ID - ref3 ER - TY - STD TI - Kayser S, Schlenk RF, Platzbecker U. Management of patients with acute promyelocytic leukemia. Leukemia. 2018;1. ID - ref4 ER - TY - STD TI - Phelan KW, Advani AS. Novel Therapies in Acute Lymphoblastic Leukemia. Current hematologic malignancy reports.2018; 1–11. ID - ref5 ER - TY - STD TI - Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2017;68. ID - ref6 ER - TY - STD TI - de Groot PM, Wu CC, Carter BW, Munden RF. The epidemiology of lung cancer. Transl Lung Cancer Res. 2018;7(3). ID - ref7 ER - TY - STD TI - Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol. 2013;31. ID - ref8 ER - TY - STD TI - Jarboe J, Gupta A, Saif W. Therapeutic human monoclonal antibodies against Cancer. 2014.In: Steinitz M. (eds) human monoclonal antibodies. Methods in molecular biology, vol 1060. Humana press, Totowa, NJ. ID - ref9 ER - TY - STD TI - Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev. 2014;257(1). ID - ref10 ER - TY - STD TI - Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013(1):39. ID - ref11 ER - TY - STD TI - Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. The Journal of Immunology. 2014;192(12). ID - ref12 ER - TY - STD TI - Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nature immunology. 2013;14(10). ID - ref13 ER - TY - STD TI - Liu Y, Cao X. Immunosuppressive cells in tumor immune escape and metastasis. J Mol Med. 2016;94(5). ID - ref14 ER - TY - STD TI - Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4 therapies in Cancer: mechanisms of action, efficacy, and limitations. Front Oncol. 2018;8. ID - ref15 ER - TY - STD TI - Hodi FS, O'day SJ, McDermott DF, Weber RW, Sosman JA, Haanen J., et al. Improved survival with ipilimumab in patients with metastatic melanoma. New England J Med. 2010; 363(8). ID - ref16 ER - TY - JOUR AU - Palmieri, D. J. AU - Carlino, M. S. PY - 2018 DA - 2018// TI - Immune Checkpoint Inhibitor Toxicity JO - Curr Oncol Rep VL - 20 UR - https://doi.org/10.1007/s11912-017-0645-y DO - 10.1007/s11912-017-0645-y ID - Palmieri2018 ER - TY - STD TI - Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma. N Engl J Hum Serv. 2015;373(1). ID - ref18 ER - TY - STD TI - Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nature Biotechnology. 2012;30(7). ID - ref19 ER - TY - STD TI - Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther. 2007;15(4). ID - ref20 ER - TY - STD TI - Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nature reviews Drug discovery. 2015;14(9). ID - ref21 ER - TY - STD TI - Nguyen T, Avci NG, Shin DH, Martinez-Velez N, Jiang H. Tune Up In Situ Autovaccination against Solid Tumors with Oncolytic Viruses. Cancers. 2018;10(6). ID - ref22 ER - TY - STD TI - Puzanov I, Milhem MM, Minor D, Hamid O, Li A, Chen L, et al . Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J Clin Oncology. 2016;34(22). ID - ref23 ER - TY - STD TI - Noonan AM, Farren MR, Geyer SM, Huang Y, Tahiri S, Ahn D, et al. Randomized phase 2 trial of the oncolytic virus pelareorep (reolysin) in upfront treatment of metastatic pancreatic adenocarcinoma. Molecular Therapy. 2016;(6):24. ID - ref24 ER - TY - STD TI - Suryawanshi YR, Zhang T, Essani K. Oncolytic viruses: emerging options for the treatment of breast cancer. Med Oncology. 2017;34(3). ID - ref25 ER - TY - STD TI - Jebar AH, Errington-Mais F, Vile RG, Selby PJ, Melcher AA, Griffin S. Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma. J Gen Virol. 2015;96(7). ID - ref26 ER - TY - STD TI - Pol J, Buqué A, Aranda F, Bloy N, Cremer I, Eggermont A, et al. Trial Watch—Oncolytic viruses and cancer therapy. Oncoimmunology. 2016;5(2). ID - ref27 ER - TY - STD TI - Shaw AR, Suzuki M. Recent advances in oncolytic adenovirus therapies for cancer. Current opinion in virology. 2016;21. ID - ref28 ER - TY - STD TI - Sokolowski NA, Rizos H, Diefenbach RJ. Oncolytic virotherapy using herpes simplex virus: how far have we come? Oncolytic virotherapy. 2015;4. ID - ref29 ER - TY - STD TI - Haddad D. Genetically engineered vaccinia viruses as agents for cancer treatment, imaging, and transgene delivery. Front Oncol. 2017;7. ID - ref30 ER - TY - STD TI - Aref S, Bailey K, Fielding A. Measles to the rescue: A review of oncolytic measles virus. Viruses. 2016;8(10). ID - ref31 ER - TY - STD TI - Ammayappan A, Russell SJ, Federspiel MJ. Recombinant mumps virus as a cancer therapeutic agent. Molecular Therapy-Oncolytics. 2016;3. ID - ref32 ER - TY - STD TI - Pizzuto MS, Silic-Benussi M, Ciminale V, Elderfield RA, Capua I, Barclay WS. An engineered avian-origin influenza A virus for pancreatic ductal adenocarcinoma virotherapy. Journal of General Virology. 2016;97(9). ID - ref33 ER - TY - STD TI - Bourhill T, Mori Y, Rancourt DE, Shmulevitz M, Johnston RN. Going (Reo) viral: factors promoting successful revival oncolytics infection. Viruses. 2018;10(8). ID - ref34 ER - TY - STD TI - Tayeb S, Zakay-Rones Z, Panet A. Therapeutic potential of oncolytic Newcastle disease virus: a critical review. Oncolytic virotherapy. 2015;4. ID - ref35 ER - TY - STD TI - Bishnoi S, Tiwari R, Gupta S, Byrareddy SN, Nayak D. Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy. Viruses. 2018 ; 10(2). ID - ref36 ER - TY - STD TI - Pol JG, Zhang L, Bridle BW, Stephenson KB, Rességuier J, Hanson S, et al. Maraba virus as a potent oncolytic vaccine vector. Molecular Therapy. 2014; 22(2). ID - ref37 ER - TY - STD TI - Angelova AL, Witzens-Harig M, Galabov AS, Rommelaere J. The Oncolytic Virotherapy era in cancer management: prospects of applying H-1 parvovirus to treat blood and solid cancers. Frontiers in oncology.2017; 7. ID - ref38 ER - TY - STD TI - Ruiz AJ, Hadac EM, Nace RA, Russell SJ. MicroRNA-detargeted mengovirus for oncolytic virotherapy. J Virol. 2016;JVI-02810. ID - ref39 ER - TY - STD TI - Matsuda T, Karube H, Aruga A. A Comparative Safety Profile Assessment of Oncolytic Virus Therapy Based on Clinical Trials. Therapeutic innovation & regulatory science.2017; 52(4). ID - ref40 ER - TY - STD TI - Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. Journal of clinical Oncology. 2015; 33(25). ID - ref41 ER - TY - STD TI - Irwin CR, Hitt MM, Evans DH. Targeting nucleotide biosynthesis: a strategy for improving the oncolytic potential of DNA viruses. Front Oncol. 2017;7. ID - ref42 ER - TY - STD TI - Delwar ZM, Kuo Y, Wen YH, Rennie, PS, Jia W. Oncolytic virotherapy blockade by microglia and macrophages requires STAT1/3. Cancer research. 2017;78(3). ID - ref43 ER - TY - STD TI - Rye IH, Trinh A, Saetersdal A, Nebdal D, Lingjaerde OC, Almendro V, et al. Intra-tumor heterogeneity defines treatment-resistant HER2+ breast tumors. Mol Oncol. 2018. ID - ref44 ER - TY - STD TI - Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013;501(7467). ID - ref45 ER - TY - STD TI - Sarinella F, Calistri A, Sette P, Palu G, Parolin C. Oncolysis of pancreatic tumour cells by a γ34. 5-deleted HSV-1 does not rely upon Ras-activation, but on the PI 3-kinase pathway. Gene Ther. 2006;13(14). ID - ref46 ER - TY - STD TI - Drost J, Clevers H. Organoids in cancer research. Nat Rev Cancer. 2018;1. ID - ref47 ER - TY - STD TI - Lai Y, Wei X, Lin S, Qin L, Cheng L, Li P. Current status and perspectives of patient-derived xenograft models in cancer research. J Hematol Oncol. 2017;(1):10. ID - ref48 ER - TY - STD TI - Carrillo MA, Zhen A, Kitchen SG. The use of the humanized mouse model in gene therapy and immunotherapy for HIV and cancer. Front Immunol. 2018;9. ID - ref49 ER - TY - STD TI - Power AT, Wang J, Falls TJ, Paterson JM, Parato KA, Lichty BD, et al. Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther. 2007;15(1). ID - ref50 ER - TY - JOUR AU - Guo, Z. S. AU - Liu, Z. AU - Bartlett, D. L. PY - 2014 DA - 2014// TI - Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity JO - Front Oncol VL - 4 ID - Guo2014 ER - TY - STD TI - Ricca JM, Oseledchyk A, Walther T, Liu C, Mangarin L, Merghoub T, et al. Pre-existing immunity to oncolytic virus potentiates its immunotherapeutic efficacy. Mol Ther. 2018;26(4). ID - ref52 ER - TY - STD TI - Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RH, Michielin O, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170(6). ID - ref53 ER - TY - STD TI - Fisher K. Striking out at disseminated metastases: the systemic delivery of oncolytic viruses. Current opinion in molecular therapeutics. 2006; 8(4). ID - ref54 ER - TY - STD TI - Wang Y, Marelli G, Howells A, Lemoine N. Oncolytic viral therapy and the immune system: a double-edged sword against cancer. Front Immunol. 2018;9. ID - ref55 ER - TY - JOUR AU - Fukuhara, H. AU - Ino, Y. AU - Todo, T. PY - 2016 DA - 2016// TI - Oncolytic virus therapy: a new era of cancer treatment at dawn JO - Cancer Sci VL - 107 UR - https://doi.org/10.1111/cas.13027 DO - 10.1111/cas.13027 ID - Fukuhara2016 ER - TY - STD TI - Liu BL, Robinson M, Han ZQ, Branston RH, English C, Reay P, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003;10(4). ID - ref57 ER - TY - STD TI - Leoni V, Vannini A, Gatta V, Rambaldi J, Sanapo M, Barboni C, et al. A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors. PLoS pathogens.2018; 14(8). ID - ref58 ER - TY - STD TI - Kowalsky SJ, Liu Z, Feist M, Berkey SE, Ma C, Ravindranathan R, et al. Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade. Mol Ther. 2018;(10):26. ID - ref59 ER - TY - STD TI - Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;1. ID - ref60 ER - TY - STD TI - Hoeller C, Michielin O, Ascierto PA, Szabo Z, Blank CU. Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma. Cancer Immun. 65(9). ID - ref61 ER - TY - STD TI - Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF, et al. Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication. Mol Ther. 2018;26(7). ID - ref62 ER - TY - STD TI - Chen CY, Hutzen B, Wedekind MF, Cripe TP. Oncolytic virus and PD-1/PD-L1 blockade combination therapy. Oncolytic virotherapy. 2018;7. ID - ref63 ER - TY - STD TI - Downs-Canner S, Guo ZS, Ravindranathan R, Breitbach CJ, O'malley ME, Jones HL, et al. Phase 1 study of intravenous oncolytic poxvirus (vvDD) in patients with advanced solid cancers. Mol Ther. 2016;24(8). ID - ref64 ER - TY - STD TI - Streby KA, Geller JI, Currier MA, Warren PS, Racadio JM, Towbin AJ, et al. Intratumoral injection of HSV1716, an oncolytic herpes virus, is safe and shows evidence of immune response and viral replication in young cancer patients. Clin Cancer Res. 2017;23(14). ID - ref65 ER - TY - STD TI - Zhang J, Tai LH, Ilkow CS, Alkayyal AA, Ananth AA, De Souza CT, et al. Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic disease. Mol Ther. 2014;22(7). ID - ref66 ER - TY - STD TI - Burke MJ. Oncolytic Seneca Valley Virus: past perspectives and future directions. Oncolytic Virotherapy. 2016;5. ID - ref67 ER - TY - STD TI - Kambara H, Okano H, Chiocca EA, Saeki Y. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res. 2005;65(7). ID - ref68 ER - TY - STD TI - Campadelli-Fiume G, Petrovic B, Leoni V, Gianni T, Avitabile E, Casiraghi C, Gatta V. Retargeting strategies for oncolytic herpes simplex viruses. Viruses. 2016;8(3). ID - ref69 ER -